AWM
TEVA icon

Accel Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Accel Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-118
Closed -$1.04K – 784
2023
Q1 		$1.04K Hold
118
– – ﹤0.01% 1167
2022
Q4 		$1.08K Hold
118
– – ﹤0.01% 961
2022
Q3 		$1K Hold
118
– – ﹤0.01% 1025
2022
Q2 		$1K Hold
118
– – ﹤0.01% 985
2022
Q1 		$1K Hold
118
– – ﹤0.01% 918
2021
Q4 		$1K Hold
118
– – ﹤0.01% 915
2021
Q3 		$1K Hold
118
– – ﹤0.01% 811
2021
Q2 		$1K Hold
118
– – ﹤0.01% 891
2021
Q1 		$1K Hold
118
– – ﹤0.01% 858
2020
Q4 		$1K Buy
+118
New +$1.13K ﹤0.01% 820

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Accel Wealth Management's TEVA Position: Q2 2023 in Review

Accel Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 118 shares — an estimated $1.04K sold.

Accel Wealth Management first reported a position in TEVA in Q4 2020 and held it in 10 quarters. The position peaked at $1.08K in Q4 2022. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Accel Wealth Management reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Accel Wealth Management sold 118 Teva Pharmaceuticals shares in Q2 2023, an estimated $1.04K.
  • Accel Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Accel Wealth Management's Teva Pharmaceuticals position peaked at $1.08K in Q4 2022.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Accel Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.